Atomoxetine in the Treatment of Binge Eating Disorder

This study has been completed.

Sponsored by:	University of Cincinnati
Information provided by:	University of Cincinnati
ClinicalTrials.gov Identifier:	NCT00327834

Purpose

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Condition	Intervention	Phase
Binge-Eating Disorder	Drug: atomoxetine	Phase IV

MedlinePlus related topics: Eating Disorders

Drug Information available for: Atomoxetine Atomoxetine hydrochloride

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

Eligibility

Criteria

Inclusion Criteria:

Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion Criteria:

Have concurrent symptoms of bulimia nervosa or anorexia nervosa
Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
Patients who are displaying clinically significant suicidality or homicidality

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00327834

Locations

United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267-0559

Sponsors and Collaborators

University of Cincinnati

Investigators

Principal Investigator:

Susan L: McElroy, MD

University of Cincinnati

More Information

Publications indexed to this study:

Study ID Numbers:	B4Z-US-X009
Study First Received:	May 17, 2006
Last Updated:	May 17, 2006
ClinicalTrials.gov Identifier:	NCT00327834
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Signs and Symptoms
Bulimia Nervosa
Signs and Symptoms, Digestive
Mental Disorders

Bulimia
Atomoxetine
Eating Disorders
Hyperphagia

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Pathologic Processes
Disease
Molecular Mechanisms of Pharmacological Action

Adrenergic Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009